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Investigation of the relationship between high-density lipoprotein-cholesterol (HDL-c) and the risk of developing cancer in a
prospective cohort of human immunodeﬁciency virus (HIV)-infected patients.
The Italian Cohort of Antiretroviral-naïve Patients Foundation Cohort is an Italian multicenter observational study recruiting HIV-
positive patients while still antiretroviral treatment-naïve, regardless of the reason since 1997.
Patients with at least 1 HDL-c value per year since enrollment and one such value before antiretroviral treatment initiation were
included. HDL-c values were categorized as either low (<39mg/dL in males or <49mg/dL in females) or normal. Cancer diagnoses
were classiﬁed as AIDS-deﬁning malignancies (ADMs) or non-AIDS-deﬁning malignancies (NADMs). Kaplan–Meier curves and Cox
proportional-hazards regression models were used.
Among 4897 patients (13,440 person-years of follow-up [PYFU]), 104 diagnoses of cancer were observed (56 ADMs, 48 NADMs)
for an overall incidence rate of 7.7 (95% conﬁdence interval [CI] 6.3–9.2) per 1000 PYFU.
Low HDL-c values at enrollment were associated with higher risk both of cancer (crude hazard ratio [HR] 1.72, 95% CI 1.16–2.56,
P=0.007) and of NADM (crude HR 2.50, 95%CI 1.35–4.76, P=0.003). Multivariate analysis showed that the risk of cancer diagnosis
was higher in patients with low HDL-c values (adjusted HR [AHR] 1.87, 95%CI 1.18–2.95, P=0.007) in older patients, those patients
more recently enrolled, and in those with low current cluster of differentiation 4+ levels, and/or high current HIV-ribonucleic acid.
The multivariate model conﬁrmed an association between HDL-c (AHR 2.61, 95% CI 1.40–4.89, P=0.003) and risk of NADM.
Low HDL-c is an independent predictor of cancer in HIV-1-infected subjects.
Abbreviations: ABCA-1 = ATP-binding cassette transporter A1, ADMs = AIDS-deﬁning malignancies, AHR = adjusted hazard
ratio, AIC = Akaike information criterion, AIDS = acquired immune deﬁciency syndrome, ApoA1 = apolipoprotein A1, ART =
antiretroviral treatment, TNF-a= tumor necrosis factor-alfa, CD4 = cluster of differentiation 4, CD8 = cluster of differentiation 8,
HBsAg= hepatitis B surface antigen, HBV= hepatitis B virus, HCC= hepatocellular carcinoma, HCV-Ab= hepatitis C virus antibody,
HDL-c = high-density lipoprotein-cholesterol, HIV = human immunodeﬁciency virus, HIV-RNA =HIV-ribonucleic acid, HPV = human
papillomavirus, HR = hazard ratio, ICONA = Italian Cohort of Antiretroviral-naïve Patients, IQR = interquartile range, IR = incidence
rate, KS = Kaposi sarcoma, LDL-c = low-density lipoprotein cholesterol, nadir = lowest ever, NADMs = non-AIDS-deﬁning
malignancies, PYFU = person-years of follow-up, SAS = statistical analysis system, VL = viral load.
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Cancer is one of the most important causes of mortality in human
immunodeﬁciency virus (HIV)-infected patients, occurring both
as acquired immune deﬁciency syndrome (AIDS)-deﬁning
malignancies (ADMs) and non-AIDS-deﬁning malignancies
(NADMs).[1,2]
Inﬂammation is a crucial pathogenetic mechanism involved in
cancer development,[3] and inﬂammation and immune activation
are highly prevalent in HIV-infected subjects despite the use of
antiretroviral treatment (ART).[4,5]
Lipid proﬁle is profoundly inﬂuenced by proinﬂammatory
state, which alters predominantly high-density lipoprotein-
cholesterol (HDL-c) composition and function.[6,7] Indeed, low
HDL-c has been associated with high levels of tumor necrosis
factor-alfa (TNF-a)[8] and predominance of a proinﬂammatory
phenotype in monocyte-derived macrophages, suggesting that
inﬂammation could be a risk factor for low HDL-c.[9]
Of late, low HDL-c values have been associated with cancer
diagnosis.[10,11] Meanwhile, apolipoprotein A1 (ApoA1), an
important component of HDL-c, has been demonstrated to have
a direct suppressive effect on tumor cells of melanoma in vitro
and in vivo.[12] This predominant role of ApoA1 was conﬁrmed
by studies that used ApoA1 HDL-c-mimetics peptides to inhibit
ovarian and colon cancer development in mouse models.[13,14]
Little is known about the predictive value of HDL-c in cancer
development in the setting of HIV infection.
HIV affects the ATP-binding cassette transporter A1 (ABCA-
1)-dependent cholesterol efﬂux through Nef protein, reducing
ApoA1 and, consequently, lowering HDL-c serum level.[15]
Baker et al[16] demonstrated that both HDL-c and ApoA1
increase after the start of ART introduction, at levels which
correspond to the degree of inﬂammation present at entry,
suggesting that activation of inﬂammation pathways contribute
to HIV-associated changes in HDL-c.
Cancer risk has also been shown to undergo changes during
ART depending on cluster of differentiation 4 (CD4) cell count
and HIV viral load (VL) modiﬁcation.
To shed light on the processes described above, the primary
aim of our study was to evaluate the association between HDL-c
levels and the development of ADMandNADM in a large cohort
of HIV-infected patients initiating ART in Italy.2. Methods
2.1. Study design and participants
This is a cohort study of all the HIV-1-infected subjects enrolled
in the Italian Cohort of Antiretroviral-Naïve Patients (ICONA)
Foundation Cohort Study with at least 1 HDL-c value per year
available since enrollment and 1 such value before ART
initiation. As annual monitoring of HDL-c is a more recent
practice, only subjects enrolled in the cohort since January 2009
were eligible for this study.
The ICONA Foundation Cohort is a cohort of HIV-infected
patients which superseded the original ICONA study (see detailed
description of this cohort elsewhere),[17] recruiting HIV-positive
patients while still ART-naïve, regardless of the reason. On
average, CD4 cell counts, HIV VL and other laboratory
parameters are measured, and clinical and therapeutical data
are collected every 4 months.
Incident cancer cases diagnosed after enrollment were
considered in the analyses, focusing on the earliest cancer
diagnosis and ignoring subsequent diagnoses in the same patient.2Prevalent cases, that is, patients with a cancer diagnosis before
enrollment in the ICONA Foundation Cohort, were excluded
from the analyses.
Malignancieswere classiﬁed asADMorNADM;ADMincluded
Kaposi sarcoma (KS), non-Hodgkin lymphoma, primary central
nervous system lymphoma, and invasive cervical cancer; NADM
included Hodgkin lymphoma, hepatocellular carcinoma (HCC),
lung cancer, larynx cancer, anal cancer, stomach cancer, colon
cancer, rectal cancer, skin cancer, melanoma, breast cancer,
prostate cancer, testicular cancer, bladder cancer, pancreas cancer,
and renal cancer.
Patients were followed up from enrollment date to earliest
cancer diagnosis, latest clinical visit, or lost-to-follow-up or
death. Data freezing for this analysis was June 2015.2.2. Statistical analysis
Results were described as median (interquartile range [IQR]) or
frequency (%), unless otherwise speciﬁed.
High-density lipoprotein-cholesterol was used either as a
continuous variable or as a categorical variable in one of the 2
classes: low (<39mg/dL in males or <49mg/dL in females) or
normal. Our analysis factored in not only the last HDL-c value
taken before cancer diagnosis, but each HDL-c value collected
over the entire study period.
Crude rates of incident cancer (incidence rate [IR]) were
calculated as the number of cancer diagnoses divided by the
number of person-years of follow-up (PYFU), andwere expressed
per 1000 PYFU; conﬁdence intervals (CIs) for the rates were
calculated assuming a Poisson distribution.
The Kaplan–Meier method was used to estimate the
probability of cancer occurrence based on HDL-c level at
enrollment; curves were compared by use of the log-rank test.
Three multivariate Cox proportional-hazards regression
models were used to evaluate the association between HDL-c
and the risk of cancer, and the risk of speciﬁc cancer categories
(ADM and NADM), adjusting for a number of potential
confounders.
At univariate analysis, we determined if HDL-c was better
modeled as a continuous variable or as a categorical variable (low
vs normal), based on the Akaike information criterion (AIC). As
the estimated AICs were very similar (1–2 points AIC difference,
with no clear evidence of one model’s superiority), HDL-c was
considered to be a categorical variable in the 3 multivariate
models.
Factors included in the multivariate models were either ﬁxed
(age, sex, smoke, hepatitis C virus-antibody [HCV-Ab], hepatitis
B surface antigen [HBsAg], lowest ever [nadir] CD4, calendar
year of enrollment) or time-updated variables (use of ART,
current CD4, current HIV-ribonucleic acid [HIV-RNA] [on the
log10 scale], current HDL-c, and current triglycerides).
Missing values of categorical variables were grouped into
speciﬁc categories, with no loss of observations at multivariate
analysis. Missing values of continuous variables, on the other
hand, led to a loss of observations, at which point the number of
events (on average 88%) effectively retained in each multivariate
model was indicated.
The multivariate models were reﬁt after additional testing of
current CD4/cluster of differentiation 8 (CD8) ratio, a known
predictive factor of non-AIDS-related events.[18] The multivariate
analyses were also restricted to that subgroup of patients exposed
to ART, and inclusion in the analyses of cancer was restricted to
those cancer diagnoses which were performed subsequent to
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after exclusion of cancer diagnoses recorded within the ﬁrst 6
months since enrollment, to exclude those diagnoses which might
be considered prevalent, rather than incident events.
All reported P values were 2-sided and considered to be
statistically signiﬁcant if below 0.05. The analyses were
performed using statistical analysis system (SAS) Software,
release 9.2 (SAS Institute, Cary, NC).2.3. Ethics
All patients signed consent forms to participate in the ICONA
Foundation Study, in accordance with the ethics standards of the
committee on human experimentation and the Helsinki Declara-
tion (1983 revision).3. Results
In all, 4897 patients participated. Demographics and clinical
characteristics are shown in Table 1.
Overall median age was 37 years (31–45), 22% were females,
20% were non-Italian subjects, and 41% were smokers; HIV
transmission was mainly by homosexual intercourse (43%). An
AIDS diagnosis before enrollment occurred in 10% of patients
and CD4+ nadir was 320 (186–454)cells/mm3. Very few patients
had a positive serologic test for HCV-Ab (9%) and for HBsAg
(3%). Median time of follow-up was 1.9 (0.42–3.93) years,
accounting for 13,440 PYFU (with incident cancer: 0.96
[0.22–2.29] years; without incident cancer: 1.92 [0.44–3.97]
years; P=0.001). During follow-up, 104 diagnoses of cancer
were reported (56 ADMs and 48NADMs); cancer characteristics
are depicted in Table 2.
Forty-eight per cent of cancers occurred 12 months after
enrollment and 80% of cancers were diagnosed after ART
initiation.KS (64%)was themost frequentADMfollowedbynon-
Hodgkin lymphoma (23%) and cervical cancer (13%). Hodgkin
lymphoma (21%)was themost frequent NADM followed by lung
and bladder cancer (for both 15%) and liver cancer (8%).
At enrollment, 2448 (50%) subjects had low HDL-c values,
and the median number of the available HDL-c determinations
during follow-up was 5 (2–10).
Patients with low as opposed to normal HDL-c values at
enrollment were less frequently male (77% vs 80%; P=0.004),
more frequently smokers (47% vs 43%; P=0.006), with a
previous diagnosis of AIDS (12% vs 7%; P<0.001), started ART
during follow-up (79% vs 69%; P<0.001), were older (38
[31–46] vs 36 [30–44] years; P<0.001), with lower CD4 nadir
(288 [141–432] vs 348 [235–480]cells/mm3; P<0.001), lower
CD4+ cell count (351 [164–534] vs 449 [293–618]cells/mm3;
P<0.001), lower CD4/CD8 ratio (0.35 [0.19–0.57] vs 0·47
[0.30–0.69]; P<0.001), higher HIV-VL (4.74 [4.07–5.36] vs
4.39 [3.67–4.92] log10copies/mL; P<0.001), lower total
lymphocytes count (1765 [1200–2370] vs 1900 [1440–2400]
cells/mm3; P<0.001), lower total cholesterol (151 [127–177] vs
174 [152–200]mg/dL; P<0.001), lower low-density lipoprotein-
cholesterol (LDL-c) (92 [72–114] vs 104 [84–126]mg/dL; P<
0.001), and higher triglycerides (124 [88–174] vs 88 [66–124]
mg/dL; P<0.001). Patients with lowHDL-c values at enrollment
also died more frequently during follow-up (2.8% vs 1.5%; P=
0.002) as compared with those with normal HDL-c values.
The overall cancer incidence rate was 7.7 (95%CI 6.3–9.2) per
1000 PYFU (ADM: 4.2 [95% CI 3.1–5.3] per 1000 PYFU;
NADM: 3.6 [95% CI 2.6–4.6] per 1000 PYFU).3Overall and NADM incidence rates signiﬁcantly differed
between subjects with normal as opposed to those with low
values of HDL-c at enrollment (overall: 5.7 [95% CI 4.2–7.8] vs
9.8 [95% CI 7.7–12.6] per 1000 PYFU; P=0.006 by univariate
Poisson regression; ADM: 3.7 [95% CI 2.5–5.4] vs 4.7 [95% CI
3.3–6.7] per 1000 PYFU; P=0.353 by univariate Poisson
regression; NADM: 2.0 [95% CI 1.2–3.5] vs 5.2 [95% CI
3.7–7.2] per 1000 PYFU; P=0.002 by univariate Poisson
regression).
Patients with incident cancer as compared with those without
(Table 1) were found to be older (45 [37–53] vs 37 [31–45]
years; P<0.001], more frequently with previous diagnosis of
AIDS (65 [62%] vs 399 [8%] events; P<0.001), with lower
CD4 nadir (179 [66–277] vs 324 [190–457] cells/mm3; P<
0.001), earlier calendar year of enrollment (2009 [2006–2011]
vs 2011 [2008–2013]; P<0.001), lower CD4 cell count (220
[85–472] vs 407 [237–580] cells/mm3; P<0.001), lower CD4/
CD8 ratio (0.26 [0.14–0.56] vs 0.42 [0.25–0.63]; P<0.001),
lower total lymphocytes count (1460 [1006–2093] vs 1820
[1320–2400] cells/mm3; P<0.001), higher HIV-VL (4.91
[3.95–5.43] vs 4.56 [3.83–5.14] log10copies/mL; P=0.011),
and lower HDL-c (35 [28–46] vs 40 [33–49]mg/dL; P=0.001)
at enrollment.
Low HDL-c values at enrollment were associated with a
higher risk of any type of cancer (crude hazard ratio [HR] 1.72,
95% CI 1.16–2.56, P=0.007) and with a higher risk of NADM
(crude HR 2.50, 95% CI 1.35–4.76, P=0.003) as shown in
Fig. 1.
At univariate analysis (Table 3), the risk of cancer was
associated with older age, not being on ART, low CD4 values,
low CD4/CD8 ratio, high HIV-RNA values, low total cholesterol
values, low HDL-c values, low LDL-c values, and high values of
fasting glucose.
Results of the multivariate analysis are reported in Table 4.
Notably, the risk of cancer diagnosis was higher in patients with
low current HDL-c values (adjusted HR [AHR] for low vs
normal: 1.87, 95% CI 1.18–2.95, P=0.007) and in those with
older age (AHR per 5-years older: 1.32, 95% CI 1.20–1.44, P<
0.001), low current CD4 levels (AHR per 100cells/mm3 higher:
0.78, 95% CI 0.68–0·91, P<0.001), high current HIV-RNA
values (AHR per 1 log10copies/mL higher: 1.69, 95% CI
1.36–2·11, P<0.001), and more recent calendar year of
enrollment (AHR per 1 more recent year: 1.10, 95% CI
1.03–1.17, P=0.005).
Low values of HDL-c still appeared to be a risk factor for risk
of ADM (Table 4), although not statistically signiﬁcant (AHR for
low vs normal: 1.28, 95% CI 0.66–2.49, P=0.475); older age
(AHR per 5 years older: 1.16, 95%CI 1.02–1.33, P=0.029), low
nadir CD4 levels (AHR per 100cells/mm3 higher: 0.68, 95% CI
0.50–0.92, P=0.011), high current HIV-RNA values (AHR per 1
log10copies/mL higher: 2.27, 95% CI 1.70–3.06, P<0.001),
and more recent calendar year of enrollment (AHR per 1 more
recent year: 1.19, 95% CI 1.08–1.31, P<0.001) were associated
with a higher risk of ADM.
The multivariate model on risk of NADM conﬁrmed
associations with low values of HDL-c (AHR for low vs normal:
2.61, 95%CI 1.40–4.89, P=0.003), older age (AHR per 5 years
older: 1.50, 95%CI 1.31–1.72, P<0.001), and low current CD4
levels (AHR per 100cells/mm3 higher: 0.73, 95% CI 0.60–0.89,
P=0.002).
Additional adjustment for current CD4/CD8 ratio (see Table 5)
led to similar conclusions with regard to the effect of low HDL-c
values (AHR of any cancer for low vs normal: 1.87, 95% CI
Table 1
Demographic, clinical, and laboratory characteristics of human immunodeﬁciency virus-infected patients in the Italian cohort of
antiretroviral-naïve patients cohort according to cancer occurrence.
Characteristic
All patients
(N=4897)
Patients with incident
cancer (n=104)
Patients without incident
cancer (n=4793) P
Patients with incident
ADM (n=56)
Patients with
incident NADM (n=48)
Age, y 37 (31–45) 45 (37–53) 37 (31–45) <0.001
∗
45 (36–50) 47 (41–55)
Males 3841 (78%) 84 (81%) 3757 (78%) 0.631† 44 (83%) 40 (83%)
Nationality 0.026†
Italian 3903 (80%) 92 (88%) 3811 (80%) 47 (84%) 45 (94%)
Non-Italian 994 (20%) 12 (12%) 982 (20%) 9 (16%) 3 (6%)
Smoke 0.466†
Current/ex 2009 (41%) 47 (45%) 1962 (41%) 24 (43%) 23 (48%)
No 2423 (50%) 48 (46%) 2375 (50%) 28 (50%) 20 (42%)
Unknown 465 (9%) 9 (9%) 456 (9%) 4 (7%) 5 (10%)
Body mass index, kg/m2 22.4 (19.4–24.7) 21.5 (18.5–24.0) 22.5 (19.4–24.7) 0.132
∗
21.7 (20.0–23.9) 22.9 (19.7–24.9)
HIV transmission risk 0.818†
IDU 474 (10%) 11 (11%) 463 (10%) 4 (7%) 7 (15%)
MSM 2114 (43%) 44 (42%) 2070 (43%) 28 (50%) 16 (33%)
Heterosexual 1941 (40%) 40 (39%) 1901 (40%) 20 (36%) 20 (42%)
Other/unknown 368 (7%) 9 (9%) 359 (7%) 4 (7%) 5 (10%)
HCV-Ab 0.598†
Positive 449 (9%) 11 (11%) 438 (9%) 3 (5%) 8 (17%)
Negative 3038 (62%) 63 (61%) 2975 (62%) 39 (70%) 24 (50%)
Unknown 1410 (29%) 30 (29%) 1380 (29%) 14 (25%) 16 (33%)
HBsAg 0.165†
Positive 160 (3%) 6 (6%) 154 (3%) 1 (2%) 5 (10%)
Negative 3241 (66%) 69 (66%) 3172 (66%) 42 (75%) 27 (56%)
Unknown 1496 (31%) 29 (28%) 1467 (31%) 13 (23%) 16 (33%)
Diagnosis of AIDS <0.001†
Yes 464 (10%) 65 (62%) 399 (8%) 56 (100%) 9 (19%)
No 4433 (90%) 39 (38%) 4394 (92%) 0 39 (81%)
Nadir CD4, cells/mm3 320 (186–454) 179 (66–277) 324 (190–457) <0.001
∗
99 (40–241) 222 (127–323)
Calendar year of enrollment <0.001
∗
2011 (2009–2013) 2009 (2006–2011) 2011 (2008–2013) 2010 (2007–2013) 2007 (2004–2010)
Calendar year of ﬁrst HIV-positive test <0.001
∗
2010 (2006–2012) 2007 (2002–2010) 2010 (2006–2012) 2009 (2005–2012) 2006 (2002–2009)
Number of patients who started ART <0.001†
3603 (74%) 101 (97%) 3502 (73%) 55 (98%) 46 (96%)
Calendar year of ART initiation <0.001
∗
2011 (2009–2013) 2009 (2007 (2011) 2011 (2009–2013) 2010 (2007–2012) 2008 (2005–2010)
Months to ART initiation
since enrollment
0.82 (0.07–6.94) 0.49 (0.07–5.07) 0.86 (0.07–6.94) 0.162
∗
0.43 (0–5.07) 0.61 (0.07–7.07)
Months of ART 23.1 (7.3–44.9) 4.1 (0.2–16.1) 23.8 (7.8–45.2) <0.001
∗
1.4 (0.2–8.6) 11.5 (3.7–29.5)
Use of statin during follow-up‡
55 (1%) 2 (2%) 53 (1%) 0.327† 0 2 (4%)
Use of fenoﬁbrate during follow-up‡
5 (0.1%) 0 5 (0.1%) 0.999† 0 0
CD4, cells/mm3 404 (229–579) 220 (85–472) 407 (237–580) <0.001
∗
128 (46–409) 263 (172–521)
CD4% 22.2 (14.8–29.0) 15.7 (9.0–27.0) 22.3 (15.0–29.0) <0.001
∗
13.9 (6.0–23.2) 20.0 (12.4–29.0)
CD8, cells/mm3 881 (619–1254) 812 (573–1043) 884 (621–1258) 0.023
∗
816 (531–1076) 812 (589–963)
CD8% 53.0 (44.2–62.0) 54.0 (45.3–67.0) 53.0 (44.1–62.0) 0.046
∗
58.1 (49.0–71.0) 50.6 (44.8–59.0)
CD4/CD8 ratio 0.41 (0.24–0.63) 0.26 (0.14–0.56) 0.42 (0.25–0.63) <0.001
∗
0.21 (0.08–0.43) 0.33 (0.22–0.71)
HIV-RNA, log10 copies/mL 4.56 (3.83–5.15) 4.91 (3.95–5.43) 4.56 (3.83–5.14) 0.011
∗
5.03 (4.71–5.49) 4.46 (3.50–5.24)
Total cholesterol, mg/dL 164 (138–189) 168 (130–193) 164 (139–189) 0.986
∗
170 (125–199) 163 (134–191)
HDL-c, mg/dL 40 (33–49) 35 (28–46) 40 (33–49) 0.001
∗
37 (30–49) 35 (28–43)
Normalx 2449 (50%) 39 (38%) 2409 (50%) 25 (45%) 14 (29%)
Lowx 2448 (50%) 65 (62%) 2384 (50%) 0.013† 31 (55%) 34 (71%)
Number of HDL-c determinations
during follow-up
5 (2–10) 3 (2–7) 5 (2–10) 0.005
∗
3 (1–5) 5 (2–11)
LDL-c, mg/dL 99 (77–120) 96 (70–125) 99 (78–120) 0.353
∗
87 (58–126) 99 (75–123)
Triglycerides, mg/dL 103 (75–152) 116 (88–161) 103 (74–151) 0.024
∗
114 (86–153) 124 (92–167)
Fasting glucose, mg/dL 86 (79–93) 87 (78–98) 86 (79–93) 0.421
∗
86 (80–96) 90 (77–100)
Total lymphocytes, 106 cells/mm3 1811 (1310–2400) 1460 (1006–2093) 1820 (1320–2400) <0.001
∗
1390 (1000–2070) 1488 (1011–2095)
All variables were measured at enrollment, unless otherwise speciﬁed.
Data reported as median (IQR) or n (%).
ADMs=AIDS-deﬁning malignancies, AIDS=acquired immune deﬁciency syndrome, ART=antiretroviral treatment, CD4= cluster of differentiation 4, CD8= cluster of differentiation 8, HBsAg=hepatitis B
surface antigen, HCV-Ab=hepatitis C virus-antibody, HDL-c=high-density lipoprotein-cholesterol, HIV=human immunodeﬁciency virus, HIV-RNA=HIV-ribonucleic acid, IDU= intravenous drug user, LDL-c=
low-density lipoprotein-cholesterol, MSM=men who have sex with men, nadir= lowest ever, NADMs=non-AIDS-deﬁning malignancies.
∗
By Wilcoxon rank-sum test.
† By chi-square or Fisher exact test, as appropriate.
‡ Use of statin or fenoﬁbrate had to precede cancer, if occurred.
x A low HDL value was deﬁned as an HDL value outside the normal range, that is,<39mg/dL in males or as an HDL value<49mg/dL in females; a normal HDL value was deﬁned as an HDL value within normal
range, that is, ≥39mg/dL in males or as an HDL value ≥49mg/dL in females.
Squillace et al. Medicine (2016) 95:36 Medicine
4
Table 2
Cancer characteristics (ﬁrst diagnosis).
Characteristic Any type (n=104) ADM (n=56) NADM (n=48) P
Time to cancer occurrence, mos 11.5 (2.6–27.5) 4.4 (1.0–18.2) 16.0 (7.2–34.3) 0.001
∗
Distribution of cancer occurrence during follow-up 0.001
∗
3 mos 28 (27%) 24 (43%) 4 (8%)
3.01–6 mos 14 (14%) 7 (13%) 7 (15%)
6.01–<12 mos 12 (12%) 3 (5%) 9 (19%)
≥12 mos 50 (48%) 22 (39%) 28 (58%)
Number of HDL-c determinations according
to cancer occurrence during follow-up
<0.001
∗
3 mos 1 (1–2) 1 (1–2) 1 (1–2)
3.01–6 mos 2 (2–2) 2 (1–2) 2 (2–2)
6.01–<12 mos 3 (2–4) 3 (3–3) 3 (2–4)
≥12 mos 6 (4–13) 5 (3–9) 8 (5–13)
Occurrence according to ART exposure 0.088†
Before or at ART start 21 (20%) 15 (27%) 6 (13%)
After ART start 83 (80%) 41 (73%) 42 (88%)
Type of malignancy
AIDS-deﬁning
Non-Hodgkin lymphoma 13 13 10
Kaposi sarcoma 36 36 4
Cervical cancer 7 7 7
Non-AIDS-deﬁning 1
Hodgkin lymphoma 10 3
Hepatocellular carcinoma 4 1
Lung cancer 7 1
Larynx cancer 1 1
Anal cancer 3 3
Stomach cancer 1 3
Colon cancer 1 2
Rectal cancer 1 2
Skin cancer 3 1
Melanoma 3 7
Breast cancer 2 1
Prostate cancer 2 1
Testicular cancer 1
Bladder cancer 7
Pancreas cancer 1
Renal cancer 1
Death for any cause 22 (21%) 8 (14%) 14 (29%) 0.091†
ADMs=AIDS-deﬁning malignancies, AIDS= acquired immune deﬁciency syndrome, ART= antiretroviral treatment, HDL-c=high-density lipoprotein-cholesterol, NADMs=non-AIDS-deﬁning malignancies.
∗
By Wilcoxon rank-sum test.
† By chi-square test.
Squillace et al. Medicine (2016) 95:36 www.md-journal.com1.14–3.06, P=0.013; AHR of ADM for low vs normal: 1.19,
95% CI 0.56–2.52, P=0.648; AHR of NADM for low vs
normal: 2.65, 95% CI 1.38–5.08, P=0.003] with a weak
association with CD4/CD8 ratio.
Among patients who had received ART (see Table 6), the
independent association between HDL-c and post-ART cancer
occurrence of any type or NADM was conﬁrmed (AHR of any
cancer for low vs normal: 2.39, 95% CI 1.44–3.96, P<0.001;
AHR of ADM for low vs normal: 1.62, 95% CI 0.75–3.48, P=
0.221; AHR of NADM for low vs normal: 3.14, 95% CI
1.59–6.21, P=0.001); among the other factors evaluated in the
model, the protective effect of a longer exposure to ART on the
risk of cancer became also evident in all the 3 models (AHR of
any cancer per 1 month longer: 0.94, 95% CI 0.93–0.95, P<
0.001; AHR of ADM per 1 month longer: 0.94, 95% CI
0.92–0.95, P<0. 001; AHR ofNADMper 1month longer: 0.94,
95% CI 0.93–0.96, P<0.001).
Finally, we reﬁt the multivariate models after exclusion of
cancer diagnoses occurred within the ﬁrst 6 months since
enrollment: current HDL-c remained an independent predictor5of any type of cancer or NADM (AHR of any cancer for low vs
normal: 1.82, 95% CI: 1.05–3.17, P=0.033; AHR of ADM for
low vs normal: 1.15, 95% CI 0.47–2.81, P=0.753; AHR of
NADM for low vs normal: 2.51, 95% CI 1.23–5.11, P=
0.012).4. Discussion
In a large cohort of ART-naïve patients seen for care in Italy, our
primary goal was to evaluate the role of HDL-c levels as a risk
factor for cancer, both ADM and NADM.
In our study, we found low HDL-c (<39 for men and<49
for women) to be an independent risk factor for cancer in
HIV, especially for NADM. Indeed, HIV-infected patients
with low HDL-c are at 87% more risk of developing
malignancies, and at more than double the risk of developing
NADMs.
The HDL-c possesses multiple anti-inﬂammatory properties,
such as inhibition of chemoattractant molecules and reduction of
expression of adhesion molecules.[19]
[20]
[24]
Figure 1. Kaplan–Meier curves estimating the probability of cancer occur-
rence according to high-density lipoprotein-cholesterol at enrollment below
normal range (continuous line) and to normal high-density lipoprotein-
cholesterol (dotted line).
Squillace et al. Medicine (2016) 95:36 MedicineInﬂammation has been purposed as a hallmark of cancer
because of activation of various types of gene mutations,
chromosomal rearrangement or ampliﬁcation and inactivation
of tumor-suppressive genes, and of infections and inﬂammatory
state by itself.[21]
Apolipoprotein A1, the most important proteic component of
HDL-c, in vitro has a direct suppressive effect on tumor cells, and
in vivo prompts tumor-inﬁltrating macrophages towards tumor
rejection.[12]
Moreover, ApoA1-mimetic peptides have demonstrated anti-
tumoral properties in ovarian and colon cancer experimental
models in vivo.[13,14]
The HDL-c and ApoA1 levels were shown to be inversely
correlated with HIV-VL,[16] and they could contribute to the
documented increased prevalence of cancer in the HIV popula-
tion.[1,2]
Moreover, recent ﬁndings reported that in HIV infection,
HDL-c could be dysfunctional in a model in vitro where HDL-c
particles extracted from HIV-infected blood samples showed
poorest anti-inﬂammatory activity on preadipocytes.[22]
The overall cancer incidence rate in our study was almost
double than that of the Italian general population,[23,24] and it
was similar to that reported in a recent study of HIV-infected
patients in France and in other European countries.[1,25–27]
Among traditional risk factors for cancer that may likely explain
the increase in incidence rate, our analysis ﬁrst of all conﬁrmed
the role of immune depression, already reported in previous
studies.[1,28–31]
At multivariate analysis, lower CD4 nadir was a risk factor for
ADM, whereas current CD4 cell count was associated with
NADM, conﬁrming the role of prior severe immune depression
on ADM and suggesting a signiﬁcant protective role of current
CD4 in NADM. At the same time, HIV-VL was associated only
with ADM, as expected. The fact that 30% of ADM occurred
before ART initiation and 56% of ADM occurred during the ﬁrst
6 months of follow-up, may likely explain the limited role of CD4
and ART in this subset of patients. And yet, among ADM
diagnoses, there was a high proportion of KS diagnoses (64%)6that occurred also in patients with high CD4 cell count, and
that may explain the lack of association between current CD4
and ADM in our study. Another potential explanation of the
limited role of current CD4 in ADM occurrence is that the mean
CD4 cell count increase during follow-up was not statistically
signiﬁcant as opposed to what occurred among subjects with a
NADM diagnosis (data not shown). The prominent role of CD4
nadir as risk factor for ADM also emerged in the analysis
considering only cancers that occurred after ART initiation
(Table 6). The strong relationship between lower nadir CD4 cell
count and increased ADM risk is well-established.[29–32]
As for NADM, there is mounting evidence for an inverse
relationship between current CD4 cell count and NADM
risk,[33–36]and almost previous studies consistently suggest that
the current/latest CD4 cell count, reﬂecting subclinical immuno-
deﬁciency, is an important marker of short-term NADM risk
(especially infection-related cancers) even in those individuals
within high CD4 cell count strata more than 200 to 350/mL.[37]
However, nadir CD4 was also independently associated with
incident NADM,[32] and also the CD4 cell recovery, which also
seemed to be an important factor for controlling the excess risk of
some cancers.[1]
Another concern is that the lack of association with ART
exposure could be due to the high incidence of ADM in the ﬁrst 6
months of therapy and to the small period of observation.
However, we demonstrated a protective role of ART when only
cancer occurrence after ART initiation was considered (Table 6).
Among NADM, Hodgkin lymphoma (21%) was the most
commonly occurring cancer, followed by lung cancer (15%) and
anal cancer (6%), as has been described in the literature.[1,38] We
reported 4 HCCs and no association with HCV-Ab positivity,
but a signiﬁcant HR at multivariate analysis associated with
HBsAg positivity (HR 2.65, 95% CI 1.01–6.98) (see Table 5).
Surprisingly, we found 7 diagnoses of bladder cancer, which is
infrequently reported in HIV population.[39] Human papilloma-
virus (HPV) colonization, predominant in HIV-infected
patients,[40] may be responsible for this increased incidence, as
demonstrated in a recent meta-analysis.[41]
In comparison with the association between low HDL-c and
type of cancer in the general population, we found a different
pattern of malignancy in HIV-infected patients; breast cancer,
endometrial cancer, pancreatic, prostate, and colon and rectal
cancer, all associated with low HDL-c in HIV-negative
population,[10,11] were poorly represented in our analysis of
NADM.
It is possible that immune perturbation due to HIV infection
and certain coinfections, such as HPV, HCV, hepatitis B virus
(HBV), and Herpes viruses, deeply inﬂuence the prevalence of
some types of cancer.
We did not ﬁnd an association with smoking and cancer
occurrence. This result could be due to the low incidence of
cancers highly associated with smoking occurrence in our
study[42]: overall, we observed 13 cancers (12.5%) highly
associated with tobacco smoking (7 lung, 1 larynx, 1 stomach,
and 3 anal cancers). Most of the cancers we observed were, in
fact, KS (36 cases, 34.6%), a cancer in which the role of smoking
remains to be elucidated.[43]
Our study does have some limitations. First, the number of
events was rather small, given the brief follow-up, This is
particularly true when results are split up into the 2 subgroups of
ADM and NADM, since most of the cancer diagnoses (especially
ADM) occurred within the ﬁrst 12 months. We therefore cannot
exclude that these diagnoses were already present at HIV
Table 3
Univariate Cox proportional-hazard models on the risk of any type of malignancy, the risk of AIDS-deﬁning malignancies and the risk of
non-AIDS-deﬁning malignancies.
Any type of malignancy ADM NADM
Characteristics
Hazard ratio (95%
conﬁdence interval) P
Hazard ratio (95%
conﬁdence interval) P
Hazard ratio (95%
conﬁdence interval) P
Age at enrollment (per 5 y older) 1.33 (1.23–1.44) <0.001 1.23 (1.10–1.37) <0.001 1.46 (1.29–1.64) <0.001
Sex
Females vs males 0.83 (0.51–1.36) 0.465 0.97 (0.51–1.84) 0.929 0.69 (0.32–1.47) 0.333
Nationality
Non-Italian vs Italian 0.67 (0.36–1.22) 0.187 0.91 (0.45–1.87) 0.805 0.37 (0.12–1.19) 0.096
Smoke
Yes vs no 1.11 (0.74–1.66) 0.615 0.99 (0.57–1.71) 0.973 1.27 (0.70–2.32) 0.432
Unknown vs no 1.33 (0.65–2.71) 0.436 0.93 (0.33–2.67) 0.897 1.97 (0.74–5.26) 0.178
HIV transmission risk 0.865 0.674 0.452
IDU vs MSM 1.03 (0.53–2.00) 0.922 0.61 (0.21–1.74) 0.355 1.75 (0.72–4.28) 0.218
Heterosexual vs MSM 0.93 (0.61–1.43) 0.741 0.74 (0.42–1.32) 0.310 1.26 (0.65–2.43) 0.497
Other vs MSM 1.27 (0.62–2.60) 0.514 0.87 (0.31–2.48) 0793 1.99 (0.73–5.43) 0.180
HCV-Ab 0.825 0.333 0.183
Positive vs negative 1.14 (0.60–2.16) 0.697 0.51 (0.16–1.65) 0.262 2.12 (0.95–4.74) 0.066
Unknown vs negative 0.92 (0.59–1.42) 0.699 0.71 (0.38–1.30) 0.265 1.26 (0.67–2.36) 0.482
HBsAg 0.264 0.272 0.030
Positive vs negative 1.72 (0.75–3.95) 0.205 0.47 (0.07–3.43) 0.458 3.63 (1.40–9.42) 0.008
Unknown vs negative 0.83 (0.54–1.29) 0.413 0.62 (0.34–1.16) 0.138 1.15 (0.62–2.14) 0.650
Nadir CD4 (per 100cells/mm3 higher) 0.66 (0.58–0.76) <0.001 0.54 (0.44–0.66) <0.001 0.82 (0.69–0.97) 0.023
Calendar year of enrollment (per year longer) 0.98 (0.93–1.03) 0.487 1.03 (0.96–1.11) 0.438 0.93 (0.87–1.00) 0.055
Calendar year of ﬁrst HIV positive test
(per year longer)
0.99 (0.96–1.03) 0.731 1.03 (0.98–1.08) 0.299 0.97 (0.92–1.00) 0.098
ART exposure
∗
Yes vs no 0.33 (0.22–0.50) <0.001 0.21 (0.12–0.37) <0.001 0.57 (0.31–1.06) 0.075
CD4 at enrollment (per 100cells/mm3 higher) 0.82 (0.75–0.89) <0.001 0.71 (0.63–0.81) <0.001 0.93 (0.83–1.04) 0.225
Current CD4 (per 100cells/mm3 higher)
∗
0.64 (0.58–0.71) <0.001 0.55 (0.47–0.64) <0.001 0.73 (0.64–084) <0.001
CD4% at enrollment (per 5% higher) 0.85 (0.77–0.94) 0.001 0.79 (0.69–0.91) 0.001 0.93 (0.81–1.06) 0.280
Current CD4% (per 5% higher)
∗
0.69 (0.62–0.77) <0.001 0.56 (0.48–0.66) <0.001 0.85 (0.73–0.98) 0.030
CD8 at enrollment (per 100cells/mm3 higher) 0.95 (0.90–0.99) 0.027 0.96 (0.90–1.02) 0.208 0.93 (0.86–1.00) 0.057
Current CD8 (per 100cells/mm3 higher)
∗
0.96 (0.91–1.01) 0.119 0.98 (0.91–1.05) 0.587 0.94 (0.86–1.01) 0.101
CD8% at enrollment (per 5% higher) 1.01 (0.99–1.02) 0.471 1.01 (1.00–1.02) 0.119 0.98 (0.90–1.05) 0.515
Current CD8% (per 5% higher)
∗
1.00 (0.99–1.01) 0.619 1.00 (0.99–1.01) 0.717 1.00 (0.99–1.01) 0.737
CD4/CD8 ratio at enrollment (per point higher) 0.21 (0.08–0.51) <0.001 0.04 (0.01–0.20) <0.001 0.69 (0.24–1.96) 0.483
Current CD4+/CD8+ ratio (per point higher)
∗
0.12 (0.06–0.28) <0.001 0.02 (0.01–0.08) <0.001 0.37 (0.15–0.92) 0.031
HIV-RNA at enrollment (per log10 copies/mL higher) 1.21 (0.99–1.48) 0.058 1.57 (1.18–2.10) 0.002 0.93 (0.70–1.22) 0.595
Current HIV-RNA (per log10 copies/mL higher)
∗
1.74 (1.51–2.00) <0.001 2.27 (1.85–2.79) <0.001 1.29 (1.04–1.62) 0.023
Total cholesterol at enrollment (per 50mg/dL higher) 0.99 (0.78–1.26) 0.957 0.91 (0.66–1.27) 0.592 1.09 (0.78–1.53) 0.617
Current total cholesterol (per 50mg/dL higher)
∗
0.62 (0.48–0.80) <0.001 0.49 (0.34–0.71) <0.001 0.76 (0.54–1.08) 0.130
HDL-c at enrollment (per 10mg/dL higher) 0.74 (0.63–0.87) <0.001 0.81 (0.65–0.99) 0.047 0.68 (0.53–0.86) 0.002
Low vs normal 1.72 (1.16–2.56) 0.007 1.28 (0.75–2.17) 0.366 2.50 (1.35–4.76) 0.003
Current HDL-c (per 10mg/dL higher)
∗
0.62 (0.53–0.74) <0.001 0.60 (0.47–0.77) <0.001 0.65 (0.51–0.82) <0.001
Low vs normal
∗
2.84 (1.88–4.30) <0.001 2.83 (1.57–5.09) <0.001 2.86 (1.60–5.11) <0.001
LDL-c at enrollment (per 50mg/dL higher) 0.81 (0.58–1.14) 0.227 0.61 (0.38–0.99) 0.046 1.09 (0.69–1.71) 0.723
Current LDL-c (per 50mg/dL higher)
∗
0.57 (0.41–0.80) 0.001 0.36 (0.21–0.60) <0.001 0.84 (0.54–1.31) 0.448
Triglycerides at enrollment (per 50mg/dL higher) 1.07 (1.00–1.15) 0.065 1.08 (0.97–1.19) 0.152 1.07 (0.96–1.19) 0.243
Current triglycerides (per 50mg/dL higher)
∗
1.03 (0.94–1.13) 0.579 1.01 (0.88–1.16) 0.893 1.04 (0.92–1.18) 0.516
ADMs=AIDS-deﬁning malignancies, AIDS=acquired immune deﬁciency syndrome, ART=antiretroviral treatment, CD4= cluster of differentiation 4, CD8= cluster of differentiation 8, HBsAg=hepatitis B
surface antigen, HCV-Ab=hepatitis C virus-antibody, HDL-c=high-density lipoprotein-cholesterol, HIV=human immunodeﬁciency virus, HIV-RNA=HIV-ribonucleic acid, LDL-c= low-density lipoprotein
cholesterol, nadir= lowest ever, NADMs=non-AIDS-deﬁning malignancies.
∗
Time-updated variable.
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events. As almost one-third of cancer diagnoses occurred within
the ﬁrst 3 months (43% for ADM), only 1 laboratory
determination (including HDL-c) was available before cancer
diagnosis: for this reason, the beneﬁt provided by the use of time-
update covariates in the analysis was fairly limited.
Additionally, our ﬁndings could be perceived to be generalized
to subjects with recent HIV diagnosis, and those with regular7monitoring of HDL-c, and therefore not necessarily representa-
tive of all HIV-infected people.
In summary, our study, for the ﬁrst time, reports an association
between HDL-c and risk of cancer in HIV infection. HDL-c is a
simple and easymarker that can be performed in every laboratory
and could sort patients at higher risk for ADM and especially for
NADM. Further follow-up will be needed to conﬁrm our
hypothesis.
Table 4
Multivariate Cox proportional-hazard models on the risk of any type of malignancy, the risk of AIDS-deﬁning malignancies, and the risk of
non-AIDS-deﬁning malignancies.
Any type of malignancy (n=91/104) ADM (n=44/56) NADM (n=47/48)
Characteristics
Adjusted hazard ratio (95%
conﬁdence interval) P
Adjusted hazard ratio (95%
conﬁdence interval) P
Adjusted hazard ratio (95%
conﬁdence interval) P
Age at enrollment (per 5 y older) 1.32 (1.20–1.44) <0.001 1.16 (1.02–1.33) 0.029 1.50 (1.31–1.72) <0.001
Sex
Females vs males 0.94 (0.56–1.56) 0.801 1.07 (0.53–2.13) 0.859 0.79 (0.36–1.72) 0.553
Smoke 0.657 0.824 0.366
Yes vs no 1.24 (0.78–1.97) 1.08 (0.56–2.08) 1.60 (0.81–3.14)
Unknown vs no 1.06 (0.48–2.37) 0.72 (0.21–2.48) 1.57 (0.53–4.65)
HCV-Ab 0.954 0.400 0.637
Positive vs negative 0.94 (0.48–1.80) 0.43 (0.13–1.46) 1.49 (0.66–3.36)
Unknown vs negative 1.10 (0.43–2.85) 0.99 (0.23–4.34) 1.18 (0.33–4.22)
HBsAg 0.480 0.732 0.117
Positive vs negative 1.67 (0.72–3.89) 0.59 (0.08–4.36) 2.59 (0.99–6.75)
Unknown vs negative 1.16 (0.47–2.89) 0.63 (0.14–2.74) 1.74 (0.53–5.74)
Nadir CD4 (per 100cells/mm3 higher) 0.91 (0.74–1.12) 0.381 0.68 (0.50–0.92) 0.011 1.20 (0.91–1.58) 0.199
Calendar year of enrollment (per year longer) 1.10 (1.03–1.17) 0.005 1.19 (1.08–1.31) <0.001 1.00 (0.92–1.09) 0.962
ART exposure
∗
Yes vs no 1.29 (0.64–2.57) 0.477 1.32 (0.53–3.31) 0.556 1.04 (0.35–3.06) 0.944
Current CD4 (per 100cells/mm3 higher)
∗
0.78 (0.68–0.91) <0.001 0.86 (0.70–1.06) 0.163 0.73 (0.60–0.89) 0.002
Current HIV-RNA (per log10 copies/mL higher)
∗
1.69 (1.36–2.11) <0.001 2.27 (1.70–3.06) <0.0001 1.15 (0.80–1.67) 0.448
Current HDL-c
Low vs normal
∗
1.87 (1.18–2.95) 0.007 1.28 (0.66–2.49) 0.475 2.61 (1.40–4.89) 0.003
Current triglycerides (per 50mg/dL higher)
∗
1.00 (0.89–1.12) 0.953 1.02 (0.86–1.21) 0.824 0.97 (0.83–1.13) 0.694
ADMs=AIDS-deﬁning malignancies, AIDS=acquired immune deﬁciency syndrome, ART= antiretroviral treatment, CD4=cluster of differentiation 4, HBsAg=hepatitis B surface antigen, HCV-Ab=hepatitis C
virus-antibody, HDL-c=high-density lipoprotein-cholesterol, HIV=human immunodeﬁciency virus, HIV-RNA=HIV-ribonucleic acid, nadir= lowest ever, NADMs=non-AIDS-deﬁning malignancies.
∗
Time-updated variable.
Table 5
Multivariate Cox proportional-hazard models on the risk of any type of malignancy, the risk of AIDS-deﬁning malignancies, and the risk of
non-AIDS-deﬁning malignancies (including CD4/CD8 ratio).
Any type of malignancy (n=77/104) ADM (n=34/56) NADM (n=43/48)
Characteristics
Hazard ratio (95%
conﬁdence interval) P
Hazard ratio (95%
conﬁdence interval) P
Hazard ratio (95%
conﬁdence interval) P
Age at enrollment (per 5 y older) 1.32 (1.19–1.46) <0.001 1.14 (0.98–1.33) 0.087 1.49 (1.30–1.72) <0.001
Sex 0.233
Females vs males 1.03 (0.59–1.78) 0.922 1.79 (0.84–3.82) 0.131 0.59 (0.24–1.41)
Smoke 0.413 0.637 0.372
Yes vs no 1.39 (0.84–2.32) 1.44 (0.68–3.05) 1.57 (0.77–3.21)
Unknown vs no 1.37 (0.60–3.15) 1.07 (0.30–3.88) 1.76 (0.59–5.26)
HCV-Ab 0.964 0.587 0.576
Positive vs negative 1.07 (0.54–2.14) 0.53 (0.15–1.83) 1.58 (0.67–3.73)
Unknown vs negative 1.11 (0.41–3.00) 1.12 (0.23–5.49) 1.10 (0.30–4.01)
HBsAg 0.269 0.918 0.097
Positive vs negative 1.95 (0.83–4.60) 0.84 (0.11–6.27) 2.65 (1.01–6.98)
Unknown vs negative 1.39 (0.53–3.63) 0.73 (0.15–3.57) 1.99 (0.59–6.75)
Nadir CD4+ (per 100cells/mm3 higher) 0.91 (0.73–1.14) 0.409 0.66 (0.47–0.91) 0.013 1.19 (0.90–1.59) 0.228
Calendar year of enrollment (per year longer) 1.08 (1.01–1.15) 0.034 1.19 (1.07–1.33) 0.002 0.98 (0.90–1.07) 0.702
ART exposure
∗
Yes vs no 1.16 (0.54–2.48) 0.699 1.05 (0.37–3.00) 0.933 1.11 (0.36–3.41) 0.861
Current CD4+ (per 100cells/mm3 higher)
∗
0.82 (0.70–0.97) 0.019 1.03 (0.81–1.31) 0.819 0.73 (0.59–0.90) 0.004
Current CD4/CD8 ratio (per point higher)
∗
0.96 (0.81–1.13) 0.594 0.77 (0.55–1.09) 0.137 1.01 (0.91–1.13) 0.823
Current HIV-RNA (per log10 copies/mL higher)
∗
1.62 (1.27–2.08) <0.001 2.15 (1.52–3.03) <0.0001 1.17 (0.80–1.73) 0.425
Current HDL-c
Low vs normal
∗
1.87 (1.14–3.06) 0.013 1.19 (0.56–2.52) 0.648 2.65 (1.38–5.08) 0.003
Current triglycerides (per 50mg/dL higher)
∗
1.00 (0.88–1.12) 0.943 1.08 (0.92–1.26) 0.366 0.93 (0.77–1.11) 0.397
ADMs=AIDS-deﬁning malignancies, AIDS=acquired immune deﬁciency syndrome, ART=antiretroviral treatment, CD4= cluster of differentiation 4, CD8= cluster of differentiation 8, HBsAg=hepatitis B
surface antigen, HCV-Ab=hepatitis C virus-antibody, HDL-c=high-density lipoprotein-cholesterol, HIV=human immunodeﬁciency virus, HIV-RNA=HIV-ribonucleic acid, nadir= lowest ever, NADMs=non-
AIDS-deﬁning malignancies.
∗
Time-updated variable.
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Table 6
Multivariate Cox proportional-hazard models on the risk of any type of malignancy, the risk of AIDS-deﬁning malignancies, and the risk of
non-AIDS-deﬁning malignancies in subjects exposed to antiretroviral treatment.
Any type of malignancy (n=71/83) ADM (n=32/41) NADM (n=39/42)
Characteristics
Adjusted hazard ratio
(95% conﬁdence interval) P-value
Adjusted hazard ratio
(95% conﬁdence interval) P
Adjusted hazard ratio
(95% conﬁdence interval) P
Age at enrollment (per 5 y older) 1.42 (1.28–1.58) <0.001 1.24 (1.06–1.45) 0.007 1.61 (1.38–1.87) <0.001
Sex 0.713 0.476 0.896
Females vs males 1.12 (0.62–2.00) 1.35 (0.59–3.09) 0.95 (0.41–2.20)
Smoke 0.405 0.980 0.299
Yes vs no 1.43 (0.84–2.42) 1.04 (0.48–2.27) 1.78 (0.86–3.68)
Unknown vs no 1.09 (0.45–2.63) 0.90 (0.24–3.34) 1.27 (0.38–4.26)
HCV-Ab 0.947 0.694 0.921
Positive vs negative 0.89 (0.43–1.85) 0.64 (0.18–2.25) 1.15 (0.46–2.89)
Unknown vs negative 1.04 (0.33–3.30) 1.51 (0.24–9.32) 0.83 (0.18–3.85)
HBsAg 0.233 0.854 0.154
Positive vs negative 2.44 (0.86–6.90) 1.25 (0.17–9.52) 3.00 (0.87–10.32)
Unknown vs negative 1.31 (0.43–3.95) 0.64 (0.11–3.85) 2.10 (0.50–8.90)
Nadir CD4+ (per 100cells/mm3 higher) <0.001 <0.001 0.047
0.59 (0.47–0.75) 0.46 (0.33–0.64) 0.75 (0.53–0.98)
Calendar year of enrollment (per more recent year) 0.048 0.836 0.002
0.94 (0.88–0.99) 1.01 (0.92–1.11) 0.88 (0.81–0.95)
Months of ART (per mo longer) 0.94 (0.93–0.95) <0.001 0.94 (0.92–0.95) <0.001 0.94 (0.93–0.96) <0.001
Current CD4 (per 100cells/mm3 higher)
∗
0.540 0.730 0.302
0.96 (0.83–1.10) 1.03 (0.86–1.25) 0.90 (0.73–1.10)
Current HIV-RNA (per log10 copies/mL higher)
∗
0.316 0.002 0.113
1.10 (0.91–1.33) 1.51 (1.16–1.96) 0.78 (0.58–1.06)
Current HDL-c <0.001 0.221 0.001
Low vs normal
∗
2.39 (1.44–3.96) 1.62 (0.75–3.48) 3.14 (1.59–6.21)
Current triglycerides (per 50mg/dL higher)
∗
0.709 0.750 0.529
0.98 (0.86–1.11) 1.03 (0.85–1.25) 0.94 (0.79–1.13)
ADMs=AIDS-deﬁning malignancies, AIDS=acquired immune deﬁciency syndrome, ART= antiretroviral treatment, CD4=cluster of differentiation 4, HBsAg=hepatitis B surface antigen, HCV-Ab=hepatitis C
virus-antibody, HDL-c=high-density lipoprotein-cholesterol, HIV=human immunodeﬁciency virus, HIV-RNA=HIV-ribonucleic acid, nadir= lowest ever, NADMs=non-AIDS-deﬁning malignancies.
∗
Time-updated variable.
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